As a general finding, CHD1L was attributed to poor prognosis and metastasis in other tumors such as gastric (Su et al., 2014), colorectal (Abbott et al., 2020), and bladder cancer (Tian et al., 2013). Here, CHD1L is linked to urinary bladder cancer.